首页|Partnership Focuses on Neurodegenerative Diseases

Partnership Focuses on Neurodegenerative Diseases

扫码查看
The FDA and the National Institutes of Health (NIH) have launched a public-private partnership to advance the understanding of and accelerate the development of treatments for rare neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).The 2 federal agencies are partnering with the Critical Path Institute (C-PATH)—an independent nonprofit, public-private partnership created in 2005 under the auspices of the FDA’s Critical Path Initiative program—on the Critical Path for Rare Neurodegenerative Diseases.

Rita Rubin

展开 >

2022

JAMA

JAMA

ISSN:0098-7484
年,卷(期):2022.328(15)